11C-MCI ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05062083 (ClinicalTrials.gov) | June 7, 2022 | 29/9/2021 | PET Imaging of Cyclooxygenase-2 in Multiple Sclerosis | PET Imaging of Cyclooxygenases in Multiple Sclerosis | Multiple Sclerosis | Drug: 11C-MCI;Drug: 11C-PS13 | National Institute of Mental Health (NIMH) | University of Maryland | Recruiting | 18 Years | 99 Years | All | 16 | Phase 2 | United States |